Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-on Therapy in High Risk Hypercholesterolemic Patients

NCT00770146 is registered in ClinicalTrials.gov with Kastle Therapeutics, LLC as lead sponsor.

NCT NCT00770146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00770146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-on Therapy in High Risk Hypercholesterolemic Patients
Lead sponsor
Kastle Therapeutics, LLC
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2008
Completion date
October 31, 2010
Enrollment
158 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

coronary heart disease, hypercholesterolemia